Strategic Partnership Potential synergy with Sysmex for expanded hemostasis diagnostics capabilities, leveraging HYPHEN BioMed’s position as a scientific and technical center of expertise in Sysmex hemostasis activities to co-develop solutions and jointly pursue international hospital and research institution contracts.

ISTH Visibility Active participation in ISTH 2025 indicates ongoing engagement with global thrombosis, hemostasis, and auto-immune disease communities, creating opportunities to showcase Lysis Timer and related tools to potential distributors, labs, and academic partners.

Global Distributor Model Existing collaborations with specialized distributors suggest room to scale through additional regional partners, enabling faster market access for innovative diagnostics tools to laboratories and hospitals across Europe and beyond.

Growth Reach Small-to-mid sized company footprint (51-200 employees) focused on niche diagnostics presents a target for mid-market laboratory networks seeking differentiated hemostasis solutions with strong technical support and expert applications knowledge.

Financial Upside Current revenue range ($0-1M) signals a growth phase with opportunities to upsell high-value diagnostic instruments or assays to research labs and hospital systems, especially through Sysmex-aligned channels and ISTH-linked partnerships.